Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617787 | 0.88 | POLB (0.43) | POLBCYP3A4TSHRSMN1; SMN2ANPEP | |
| SCHEMBL16646026 | 0.84 | POLB (0.43) | POLBCYP3A4TSHRSLC6A2SMN1; SMN2 | |
| SCHEMBL16617819 | 0.80 | CYP3A4 (0.48) | POLBCYP3A4TSHRSMN1; SMN2ANPEP | |
| SCHEMBL16617817 | 0.80 | CYP3A4 (0.48) | POLBCYP3A4TSHRSMN1; SMN2ANPEP | |
| SCHEMBL16624854 | 0.79 | POLB (0.48) | POLBCYP3A4TSHRSLC6A2SMN1; SMN2 | |
| SCHEMBL16617407 | 0.78 | POLB (0.44) | POLBCYP3A4TSHRSLC6A2SMN1; SMN2 | |
| SCHEMBL16624853 | 0.78 | POLB (0.44) | POLBCYP3A4TSHRSLC6A2SMN1; SMN2 | |
| SCHEMBL16617406 | 0.78 | POLB (0.44) | POLBCYP3A4TSHRSLC6A2SMN1; SMN2 | |
| SCHEMBL16617792 | 0.78 | CYP3A4 (0.44) | POLBCYP3A4TSHRSMN1; SMN2ANPEP | |
| SCHEMBL16617791 | 0.78 | CYP3A4 (0.44) | POLBCYP3A4TSHRSMN1; SMN2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055314-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | POLB 3196/4885CYP3A4 4149/4885TSHR 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.